Kidney Cancer

>

CURE’s kidney cancer page is an extensive resource of cancer information featuring the latest kidney cancer news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on kidney cancer.

Latest News

Patient-reported outcomes were similar for Fotivda with or without Opdivo in advanced clear cell RCC: © stock.adobe.com
Outcomes May Be Consistent With Fotivda Alone or With Opdivo in Kidney Cancer Subset

February 15th 2025

Patient-reported outcomes were similar for Fotivda with or without Opdivo in advanced clear cell RCC.

Opdivo plus Cometyx resulted in a benefit versus Sutent in the first-line of advanced renal cell carcinoma treatment. © stock.adobe.com
Opdivo Plus Cometyx Safe, Effective in Advanced Renal Cell Carcinoma

February 15th 2025

Results were consistent with research in advanced renal cell carcinoma treated with Cabometyx, Opdivo and Yervoy: © SciePro - stock.adobe.com.
Cabometyx Combo Maintains Progression-Free Survival Benefit in Advanced RCC

February 15th 2025

Among patients with clear cell renal cell carcinoma, improved responses were observed with Lenvima plus Welireg versus Keytruda plus Lenvima. © unlimit3d - stock.adobe.com
Antitumor Activity Elicited in ccRCC Following Lenvima/Welireg Treatment

February 15th 2025

1.34 mg of Fotivda provided decreased tumor size and may be more tolerable than an 0.89-mg dose in RCC: © Axel Kock - stock.adobe.com
FDA-Approved Fotivda Dose More Effective Than Reduced Dose in RCC

February 15th 2025

More News